Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yu Imai

Showing results (51-60 of 73) with videos related to

Pageof 8
Sort By:
Urologic Oncology|May 19, 2026
Beyond PSA90: Deep PSA response predicts outcomes in nonmetastatic CRPCShuhei Hara, Keiichiro Mori, Ryotaro Yamaguchi, et al.
Clinical Genitourinary Cancer|April 15, 2026
Real-World Effectiveness and Treatment Persistence of Darolutamide, Apalutamide, and Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer: A Multicenter StudyShuhei Hara, Keiichiro Mori, Masaki Hashimoto, et al.
The Prostate|April 6, 2025
PSA Absolute Value Versus PSA Response Rate: Which Is More Valuable for Estimating Survival Outcomes With ARPI Treatment for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in Real-World Analyses?Tatsuya Shimomura, Naoki Otsuka, Fumihiko Urabe, et al.
International Journal of Clinical Oncology|July 15, 2026
Real-world evaluation of primary prophylactic use of granulocyte colony-stimulating factor in patients with metastatic castration-sensitive prostate cancer treated with triplet therapyMasataka Kubo, Fumihiko Urabe, Kojiro Tashiro, et al.
BJU International|July 19, 2025
Clinical features of medication-related osteonecrosis of the jaw in prostate cancer managementYuma Goto, Fumihiko Urabe, Yue Ogihara, et al.
Clinical Genitourinary Cancer|November 25, 2023
Clinical Significance of Intraductal Carcinoma of the Prostate After High-Dose Brachytherapy With External Beam Radiation Therapy: A Single Institution Series and an Updated Meta-AnalysisKeiichiro Miyajima, Shun Sato, Naoki Uchida, et al.
Clinical Genitourinary Cancer|April 19, 2024
Site-Specific Differences of Eligibility for Adjuvant Immunotherapy Among Urothelial Carcinoma Patients Treated With Radical Surgery: Results From a Multicenter Cohort StudyChisato Narita, Fumihiko Urabe, Wataru Fukuokaya, et al.
Japanese Journal of Clinical Oncology|January 17, 2025
Evaluation of optimal timing and therapeutic efficacy of radium-223 therapy for metastatic castration-resistant prostate cancer: a multicenter collaborative studyFumihiko Urabe, Soshi Kadena, Kojiro Tashiro, et al.
Japanese Journal of Clinical Oncology|October 19, 2024
Optimal timing for initiating androgen receptor signaling inhibitor therapy in patients with nonmetastatic castration-resistant prostate cancer: a multicenter collaborative studyShuhei Hara, Fumihiko Urabe, Kojiro Tashiro, et al.
Translational Andrology and Urology|June 10, 2024
Does age impact clinical outcomes of radical nephroureterectomy in the elderly?-results from a multicenter retrospective studyMimu Ishikawa, Katsuki Muramoto, Kentaro Yoshihara, et al.
Pageof 8

Showing results (51-60 of 73) with videos related to

Sort By:
Pageof 8
Urologic Oncology|May 19, 2026
Beyond PSA90: Deep PSA response predicts outcomes in nonmetastatic CRPCShuhei Hara, Keiichiro Mori, Ryotaro Yamaguchi, et al.
Clinical Genitourinary Cancer|April 15, 2026
Real-World Effectiveness and Treatment Persistence of Darolutamide, Apalutamide, and Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer: A Multicenter StudyShuhei Hara, Keiichiro Mori, Masaki Hashimoto, et al.
The Prostate|April 6, 2025
PSA Absolute Value Versus PSA Response Rate: Which Is More Valuable for Estimating Survival Outcomes With ARPI Treatment for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in Real-World Analyses?Tatsuya Shimomura, Naoki Otsuka, Fumihiko Urabe, et al.
International Journal of Clinical Oncology|July 15, 2026
Real-world evaluation of primary prophylactic use of granulocyte colony-stimulating factor in patients with metastatic castration-sensitive prostate cancer treated with triplet therapyMasataka Kubo, Fumihiko Urabe, Kojiro Tashiro, et al.
BJU International|July 19, 2025
Clinical features of medication-related osteonecrosis of the jaw in prostate cancer managementYuma Goto, Fumihiko Urabe, Yue Ogihara, et al.
Clinical Genitourinary Cancer|November 25, 2023
Clinical Significance of Intraductal Carcinoma of the Prostate After High-Dose Brachytherapy With External Beam Radiation Therapy: A Single Institution Series and an Updated Meta-AnalysisKeiichiro Miyajima, Shun Sato, Naoki Uchida, et al.
Clinical Genitourinary Cancer|April 19, 2024
Site-Specific Differences of Eligibility for Adjuvant Immunotherapy Among Urothelial Carcinoma Patients Treated With Radical Surgery: Results From a Multicenter Cohort StudyChisato Narita, Fumihiko Urabe, Wataru Fukuokaya, et al.
Japanese Journal of Clinical Oncology|January 17, 2025
Evaluation of optimal timing and therapeutic efficacy of radium-223 therapy for metastatic castration-resistant prostate cancer: a multicenter collaborative studyFumihiko Urabe, Soshi Kadena, Kojiro Tashiro, et al.
Japanese Journal of Clinical Oncology|October 19, 2024
Optimal timing for initiating androgen receptor signaling inhibitor therapy in patients with nonmetastatic castration-resistant prostate cancer: a multicenter collaborative studyShuhei Hara, Fumihiko Urabe, Kojiro Tashiro, et al.
Translational Andrology and Urology|June 10, 2024
Does age impact clinical outcomes of radical nephroureterectomy in the elderly?-results from a multicenter retrospective studyMimu Ishikawa, Katsuki Muramoto, Kentaro Yoshihara, et al.
Pageof 8